Maghfour Jalal, Rietcheck Hope R, Rundle Chandler W, Runion Taylor M, Jafri Zainab A, Dercon Sam, Lio Peter, Fernandez Jon, Fujita Mayumi, Dellavalle Robert P, Yardley Helena
J Drugs Dermatol. 2020 Dec 1;19(12):1204-1208. doi: 10.36849/JDD.2020.5464.
Atopic dermatitis (AD) is a chronic skin disorder characterized by pruritus, erythema and excoriation. While AD has a multifactorial etiology, neuro-signaling pathways are now recognized to play an essential role in the pathogenesis of AD, particularly pruritus. Neuromodulators, such as topical naltrexone, are being utilized in AD treatment. Another class of neuromodulator, Palmitoylethanolamide (PEA), has demonstrated effectiveness in the treatment of itch, excoriation and erythema in AD patients. Phytocannabinoids including cannabidiol (CBD) are becoming increasingly accessible to the public and continue to be advertised for their efficacy to treat inflammatory skin disorders such as eczema. However, no human studies have been conducted to support the claim. Therefore, this study aimed to explore the effects of CBD in individuals with self-reported eczema. Twenty individuals consented to participate and 16 completed a 28-item online questionnaire assessing subjects’ disease severity using Patient Oriented Eczema Measure (POEM) and psychosocial burden of their disease through the emotional domain of Quality of Life Hand Eczema Questionnaire (QOLHEQ). Findings demonstrated a significant reduction in the mean score of POEM from baseline (mean ±SE: 16±1.35) and at a two weeks interval (8.25 ±1.80), P<0.0007. Similar reduction was seen in emotional domain of QOLHEQ from a mean score of 20.9±2.06 to 8.375 ±1.609 at 2 week-interval, P<0.004. 67% of subjects reported a decrease in itch and 50% perceived an improvement in their eczema by more than 60%. This observational study shed light on the potential clinical utility of topical CBD in the treatment of atopic dermatitis. J Drugs Dermatol. 2020;19(12): doi:10.36849/JDD.2020.5464.
特应性皮炎（AD）是一种以瘙痒、红斑和抓痕为特征的慢性皮肤疾病。虽然AD的病因是多因素的，但神经信号通路现在被认为在AD的发病机制中起着至关重要的作用，尤其是瘙痒。神经调节剂，如外用纳曲酮，正在用于AD的治疗。另一类神经调节剂，棕榈酰乙醇胺（PEA），已证明对AD患者的瘙痒、抓痕和红斑治疗有效。包括大麻二酚（CBD）在内的植物大麻素越来越容易被公众获取，并且继续因其治疗炎症性皮肤病如湿疹的功效而被宣传。然而，尚未进行人体研究来支持这一说法。因此，本研究旨在探讨CBD对自我报告患有湿疹的个体的影响。20名个体同意参与，16名完成了一份28项的在线问卷，使用患者导向性湿疹量表（POEM）评估受试者的疾病严重程度，并通过生活质量手部湿疹问卷（QOLHEQ）的情感领域评估其疾病的心理社会负担。结果显示，POEM的平均得分从基线（平均值±标准误：16±1.35）和两周间隔时（8.25±1.80）显著降低，P<0.0007。QOLHEQ情感领域也有类似的降低，从平均得分20.9±2.06降至两周间隔时的8.375±1.609，P<0.004。67%的受试者报告瘙痒减轻，50%的受试者认为其湿疹改善超过60%。这项观察性研究揭示了外用CBD在治疗特应性皮炎方面的潜在临床应用价值。《药物皮肤病学杂志》。2020年；19（12）：doi:10.36849/JDD.2020.5464 。
